StoneX Group’s Theriva Biologics TOVX Stock Holding History

StoneX Group’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-22,280	Closed	-$4.36K	–	1568
2026 Q1	$4.36K	Sell	22,280 -14,937	-40%	-$2.94K	﹤0.01%	886
2025 Q4	$7.83K	Buy	+37,217	New	+$11K	﹤0.01%	1014

Other funds holding TOVX

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

StoneX Group's TOVX Position: Q2 2026 in Review

StoneX Group sold out of Theriva Biologics (TOVX) in Q2 2026, closing a stake of 22,280 shares — an estimated $4.36K sold.

StoneX Group first reported a position in TOVX in Q4 2025 and held it in 2 quarters. The position peaked at $7.83K in Q4 2025. 26 funds tracked by Wall St. Rank hold TOVX as of Q2 2026.

StoneX Group reported no remaining Theriva Biologics position as of Q2 2026 after selling out during the quarter.
StoneX Group sold 22,280 Theriva Biologics shares in Q2 2026, an estimated $4.36K.
StoneX Group first reported a position in Theriva Biologics in Q4 2025 and held it in 2 quarters.
StoneX Group's Theriva Biologics position peaked at $7.83K in Q4 2025.
26 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2026.

Based on StoneX Group's 13F filing for Q2 2026, filed 12 Aug 2026.